Abstract
This study was performed to estimate the effects of risedronate on mandibular bone density, bone structure, and bone metabolism in established glucocorticoid-induced osteoporosis in growing rats. The rats were given oral risedronate at 0, 0.5, or 1.0 mg per kilogram per day for 4 weeks after the administration of oral prednisolone at 30 mg per kilogram per 2 days for 6 weeks. Trabecular and cortical bone masses were analyzed by using peripheral quantitative computed tomography, and bone structure and bone formation were measured by using static and dynamic histomorphometry. In trabecular bone, risedronate improved the prednisolone-induced decreases in bone cross-sectional area and bone mineral content. Risedronate increased bone density and also formed dense bone microarchitecture by reducing the bone turnover rate. In cortical bone, risedronate improved the prednisolone-induced decreases in bone cross-sectional area and bone mineral content without affecting bone density by increasing the mineralizing surface. Risedronate improved prednisolone-induced retardation of trabecular and cortical bone growth, but the bone turnover in these 2 sites was regulated differently in the growing rat mandibles.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Orthodontics and Dentofacial Orthopedics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
